These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26267531)

  • 1. Tumor Heterogeneity: Focus on the Leaves, the Trees, or the Forest?
    Parker JS; Perou CM
    Cancer Cell; 2015 Aug; 28(2):149-50. PubMed ID: 26267531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and molecular relevance of mutant-allele tumor heterogeneity in breast cancer.
    Ma D; Jiang YZ; Liu XY; Liu YR; Shao ZM
    Breast Cancer Res Treat; 2017 Feb; 162(1):39-48. PubMed ID: 28093659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI in residual tumor size measurement in patient with breast cancer receiving neoadjuvant chemotherapy calls for caution.
    Wu LM; Hu J; Xu JR
    Breast Cancer Res Treat; 2012 Aug; 135(1):319-20. PubMed ID: 22850894
    [No Abstract]   [Full Text] [Related]  

  • 4. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer.
    Klein CA; Blankenstein TJ; Schmidt-Kittler O; Petronio M; Polzer B; Stoecklein NH; Riethmüller G
    Lancet; 2002 Aug; 360(9334):683-9. PubMed ID: 12241875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methodological Advancements for Investigating Intra-tumoral Heterogeneity in Breast Cancer at the Bench and Bedside.
    Baek M; Chang JT; Echeverria GV
    J Mammary Gland Biol Neoplasia; 2020 Dec; 25(4):289-304. PubMed ID: 33300087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival.
    Morris LG; Riaz N; Desrichard A; Şenbabaoğlu Y; Hakimi AA; Makarov V; Reis-Filho JS; Chan TA
    Oncotarget; 2016 Mar; 7(9):10051-63. PubMed ID: 26840267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity.
    Zhong Q; Rüschoff JH; Guo T; Gabrani M; Schüffler PJ; Rechsteiner M; Liu Y; Fuchs TJ; Rupp NJ; Fankhauser C; Buhmann JM; Perner S; Poyet C; Blattner M; Soldini D; Moch H; Rubin MA; Noske A; Rüschoff J; Haffner MC; Jochum W; Wild PJ
    Sci Rep; 2016 Apr; 6():24146. PubMed ID: 27052161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrative deep-sequencing analysis of cancer samples: discoveries and clinical challenges.
    Roukos D
    Pharmacogenomics J; 2013 Jun; 13(3):205-8. PubMed ID: 23296155
    [No Abstract]   [Full Text] [Related]  

  • 9. Rare Mutations in Cancer Drug Resistance and Implications for Therapy.
    Beckman RA; Loeb LA
    Clin Pharmacol Ther; 2020 Sep; 108(3):437-439. PubMed ID: 32648584
    [No Abstract]   [Full Text] [Related]  

  • 10. Intratumor heterogeneity: evolution through space and time.
    Swanton C
    Cancer Res; 2012 Oct; 72(19):4875-82. PubMed ID: 23002210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances and current issues in single-cell sequencing of tumors.
    Sun HJ; Chen J; Ni B; Yang X; Wu YZ
    Cancer Lett; 2015 Aug; 365(1):1-10. PubMed ID: 26003306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional biases in mutation screening due to intratumoural heterogeneity of prostate cancer.
    Kim TM; Jung SH; Baek IP; Lee SH; Choi YJ; Lee JY; Chung YJ; Lee SH
    J Pathol; 2014 Aug; 233(4):425-35. PubMed ID: 24870262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SpliceHetero: An information theoretic approach for measuring spliceomic intratumor heterogeneity from bulk tumor RNA-seq.
    Kim M; Lee S; Lim S; Kim S
    PLoS One; 2019; 14(10):e0223520. PubMed ID: 31644551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delineating cancer evolution with single-cell sequencing.
    Navin NE
    Sci Transl Med; 2015 Jul; 7(296):296fs29. PubMed ID: 26180099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastasis awakening: the challenges of targeting minimal residual cancer.
    Polzer B; Klein CA
    Nat Med; 2013 Mar; 19(3):274-5. PubMed ID: 23467237
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical implications of tumor-cell heterogeneity.
    Schnipper L
    N Engl J Med; 1986 May; 314(22):1423-31. PubMed ID: 3517651
    [No Abstract]   [Full Text] [Related]  

  • 17. A population genetics perspective on the determinants of intra-tumor heterogeneity.
    Hu Z; Sun R; Curtis C
    Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):109-126. PubMed ID: 28274726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer intra-tumor heterogeneity.
    Martelotto LG; Ng CK; Piscuoglio S; Weigelt B; Reis-Filho JS
    Breast Cancer Res; 2014 May; 16(3):210. PubMed ID: 25928070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity.
    Andor N; Graham TA; Jansen M; Xia LC; Aktipis CA; Petritsch C; Ji HP; Maley CC
    Nat Med; 2016 Jan; 22(1):105-13. PubMed ID: 26618723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour heterogeneity and the evolution of polyclonal drug resistance.
    Burrell RA; Swanton C
    Mol Oncol; 2014 Sep; 8(6):1095-111. PubMed ID: 25087573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.